Real-world effectiveness of azacitidine in treatment-naive patients with higher-risk myelodysplastic syndromes by Rajakumaraswamy, N, Gandhi, M, Wei, AH, Sallman, DA, Daver, NG, Mo, S, Iqbal, S, Karalliyadda, R, Chen, M, Wang, Y, Vyas, P

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study by Garcia-Manero, G, Daver, NG, Xu, J, Chao, M, Chung, T, Tan, A, Wang, V, Wei, A, Vyas, P, Sallman, DA

TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions by Daver, NG, Maiti, A, Kadia, TM, Vyas, P, Majeti, R, Wei, AH, Garcia-Manero, G, Craddock, C, Sallman, DA, Kantarjian, HM

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results by Daver, NG, Vyas, P, Kambhampati, S, Al Malki, MM, Larson, RA, Asch, AS, Mannis, GN, Chai-Ho, W, Tanaka, TN, Bradley, TJ, Jeyakumar, D, Wang, ES, Xing, G, Chao, M, Ramsingh, G, Renard, C, Lal, I, Zeidner, JF, Sallman, DA

A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies by Lachowiez, CA, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, TM, Masarova, L, Takahashi, K, Tippett, GD, Smith, S, Garcia, JS, Bose, P, Jabbour, E, Ravandi, F, Daver, NG, Garcia-Manero, G, Stoilova, B, Vyas, P, Kantarjian, HM, Konopleva, M, Dinardo, CD

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies by Lachowiez, CA, Garcia, JS, Borthakur, G, Loghavi, S, Zeng, Z, Tippett, GD, Kadia, TM, Masarova, L, Yilmaz, M, Maiti, A, Bose, P, Takahashi, K, Jabbour, E, Ravandi, F, Daver, NG, Garcia-Manero, G, Vyas, P, Kantarjian, HM, Konopleva, M, Dinardo, CD

Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase ib results by Daver, NG, Vyas, P, Kambhampati, S, Al Malki, MM, Larson, RA, Asch, AS, Mannis, G, Chai-Ho, W, Tanaka, TN, Bradley, TJ, Jeyakumar, D, Wang, ES, Sweet, K, Kantarjian, HM, Garcia-Manero, G, Komrokji, R, Xing, G, Ramsingh, G, Renard, C, Zeidner, JF, Sallman, DA

Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study by Sallman, DA, Al Malki, MM, Asch, AS, Wang, ES, Jurcic, JG, Bradley, TJ, Flinn, IW, Pollyea, DA, Kambhampati, S, Tanaka, TN, Zeidner, JF, Garcia-Manero, G, Jeyakumar, D, Komrokji, R, Lancet, J, Kantarjian, HM, Gu, L, Zhang, Y, Tan, A, Chao, M, O'Hear, C, Ramsingh, G, Lal, I, Vyas, P, Daver, NG

A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies by Lachowiez, CA, Loghavi, S, Zeng, Z, Tanaka, T, Kim, YJ, Uryu, H, Turkalj, S, Jakobsen, NA, Luskin, MR, Duose, DY, Tidwell, RSS, Short, NJ, Borthakur, G, Kadia, TM, Masarova, L, Tippett, GD, Bose, P, Jabbour, EJ, Ravandi, F, Daver, NG, Garcia-Manero, G, Kantarjian, H, Garcia, JS, Vyas, P, Takahashi, K, Konopleva, M, DiNardo, CD

A phase 1B/2 study of the CD123-targeting antibody-drug conjugate pivekimab sunirine (IMGN632) in combination with venetoclax (VEN) and azacitidine (AZA) for patients with CD123-po... by Daver, NG, Montesinos, P, Aribi, A, Martinelli, G, Altman, J, Roboz, G, Wang, ES, Burke, PW, Jeyakumar, D, Walter, RB, DeAngelo, DJ, Erba, HP, Advani, A, Gastaud, L, Thomas, X, Todisco, E, Pemmaraju, N, Mendez, L, de la Fuente, A, Gaidano, G, Curti, A, Boissel, N, Recher, C, Schliemann, C, Vyas, P, Sloss, CM, Wang, J, Malcolm, KA, Zweidler‐McKay, PA, Sweet, KL

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MD... by Stahl, M, Bewersdorf, JP, Xie, Z, Porta, MGD, Komrokji, R, Xu, ML, Abdel-Wahab, O, Taylor, J, Steensma, DP, Starczynowski, DT, Sekeres, MA, Sanz, G, Sallman, DA, Roboz, GJ, Platzbecker, U, Patnaik, MM, Padron, E, Odenike, O, Nimer, SD, Nazha, A, Majeti, R, Loghavi, S, Little, RF, List, AF, Kim, TK, Hourigan, CS, Hasserjian, RP, Halene, S, Griffiths, EA, Gore, SD, Greenberg, P, Figueroa, ME, Fenaux, P, Efficace, F, DeZern, AE, Daver, NG, Churpek, JE, Carraway, HE, Buckstein, R, Brunner, AM, Boultwood, J, Borate, U, Bejar, R, Bennett, JM, Wei, AH, Santini, V, Savona, MR, Zeidan, AM